1. Home
  2. NCNA vs XBIO Comparison

NCNA vs XBIO Comparison

Compare NCNA & XBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NuCana plc

NCNA

NuCana plc

N/A

Current Price

$1.09

Market Cap

4.0M

Sector

Health Care

ML Signal

N/A

Logo Xenetic Biosciences Inc.

XBIO

Xenetic Biosciences Inc.

HOLD

Current Price

$2.16

Market Cap

4.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NCNA
XBIO
Founded
1997
N/A
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.0M
4.7M
IPO Year
2017
2011

Fundamental Metrics

Financial Performance
Metric
NCNA
XBIO
Price
$1.09
$2.16
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 75.0K
21.7K
Earning Date
11-12-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 38.52
EPS
★ N/A
N/A
Revenue
N/A
★ $2,976,411.00
Revenue This Year
N/A
$2.37
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 19.04
52 Week Low
$0.95
$1.58
52 Week High
$4.55
$4.94

Technical Indicators

Market Signals
Indicator
NCNA
XBIO
Relative Strength Index (RSI) 43.62 44.16
Support Level $0.95 N/A
Resistance Level $1.40 $2.53
Average True Range (ATR) 0.06 0.15
MACD 0.02 0.05
Stochastic Oscillator 47.73 71.01

Price Performance

Historical Comparison
NCNA
XBIO

About NCNA NuCana plc

NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States and the United Kingdom.

About XBIO Xenetic Biosciences Inc.

Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing immuno-oncology technologies addressing difficult-to-treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors. Its product pipeline consists of two key programs, XBIO-015 and XBIO-020, which are being developed to address pancreatic carcinoma and solid tumours.

Share on Social Networks: